Description

4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Hydrochloride is a high-purity, small molecule pharmaceutical intermediate and research chemical of significant commercial and scientific interest. This compound is a key synthetic precursor in the development of targeted kinase inhibitors, offering critical value for drug discovery and process chemistry. It is primarily needed by pharmaceutical R&D laboratories, contract manufacturing organizations (CMOs), and academic institutions engaged in oncology and signal transduction research. The product is supplied with a Certificate of Analysis to ensure batch-to-batch consistency and traceability.

Application

• Pharmaceutical Intermediate: Critical building block in the synthesis of novel tyrosine kinase inhibitors (TKIs) for targeted cancer therapies.
• Biochemical Research: Used as a reference standard and active pharmaceutical ingredient (API) precursor in preclinical studies and mechanism-of-action research.
• Process Development: Serves as a key starting material (KSM) or advanced intermediate in the scale-up and optimization of API manufacturing processes.
• Academic Research: Employed in university and institutional labs for studying structure-activity relationships (SAR) in quinazoline-based compounds.
• Contract Manufacturing: Supplied to CMOs and CDMOs for the production of clinical trial materials and commercial drug substances under GMP guidelines.
• Library Synthesis: Used for the generation of focused compound libraries for high-throughput screening in drug discovery programs.

Basic Information

Product Name	4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Hydrochloride
CAS No.	184475-55-6
Molecular Formula	C22H25ClFN4O3 • HCl
Molecular Weight	484.82 g/mol (Free base: 448.91 g/mol)
Synonyms	N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine hydrochloride; Gefitinib Impurity; Gefitinib Intermediate; ZD1839 Intermediate; IRESSA Intermediate; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-, monohydrochloride; 184475-55-6 (CAS)
EINECS	Contact for details

Quality Control

Our 4-(3-Chloro-4-Fluorophenylamino)-7-Methoxy-6-[3-(4-Morpholinyl)Propoxy]Quinazoline Hydrochloride is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC, NMR, and MS, to ensure identity, purity, and conformity to client specifications. A comprehensive Certificate of Analysis (COA) detailing all test results is provided with every shipment. We support development and commercial projects requiring compliance with GMP, ICH Q7, and other relevant pharmaceutical guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥98.0%
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm
Related Substances (HPLC)	Individual impurity ≤0.5%; Total impurities ≤2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.